Skip to the answer

Tesamorelin Injection Uses, Dosage, Side Effects and Interactions

Brand names
Egrifta

Egrifta was the first tesamorelin injection product the FDA approved, in 2010.

Egrifta Sv

Egrifta Sv is a brand of tesamorelin injection that comes as an injection.

Egrifta Wr

Egrifta Wr is a brand name for tesamorelin injection.

Tesamorelin Injection is a growth hormone-releasing factor medicine used to reduce excess belly fat in adults with HIV who have lipodystrophy.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Tesamorelin InjectionType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Tesamorelin Injection in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Tesamorelin (Egrifta WR) is a specialist injection that reduces excess belly fat in adults with HIV and lipodystrophy (abnormal fat distribution) by prompting the pituitary gland to release more of your own growth hormone; it has been on the U.S. market since about 2010, is not available as a generic, and is not a weight-loss drug. Most people manage it fairly well, though joint and muscle aches, swelling in the hands or feet, and redness or itching where the shot goes in are common. Watch your blood sugar, since it can raise glucose or bring on diabetes, and expect checks of it and of IGF-1, a growth factor the medicine raises.

Key Takeaways From the HelloPharmacist Team

  • Expect to give yourself a once-daily shot under the skin of your belly, rotating spots and avoiding the navel, scars and bruises.
  • Swirl gently to mix, never shake, use only if clear, and know one mixed vial lasts 7 days at room temperature.
  • Stop it and get medical help right away for rash, hives, itching or flushing, which can signal an allergic reaction.
  • Do not use it during pregnancy or with active cancer, and tell your doctor right away about a pregnancy or any new growth.

How we write and review this content: our editorial policy

Tesamorelin Injection by the Numbers

Strengths
1
in one form
Makers and packagers
1
Earliest FDA record
2010
Rank by Medicaid prescriptions
#1,489 of 1,682 drugs
More prescriptions than 11% of the 1,682 drugs we measure
287 prescriptions, Q1–Q4 2025

Patient Information Guide for Tesamorelin Injection

What It’s Used For

Tesamorelin Injection is used for one supported purpose:

  • EGRIFTA WR reduces excess abdominal fat in HIV-infected adults with lipodystrophy.
  • It is not for weight loss.
  • Long-term heart safety has not been established.

How It Works

Tesamorelin binds to growth hormone-releasing factor receptors, much like your body's own hormone. This prompts the pituitary gland to make and release growth hormone. Growth hormone helps build tissue and break down fat, partly through IGF-1.

Drug Class

Drug Class

  • Growth Hormone Releasing Factor Analog
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Growth Hormone Releasing Factor Analog

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)

None listed for Tesamorelin Injection in the FDA’s index.

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)
  • Increased GHRH Activity

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Tesamorelin Injection in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Somatropin and somatropin agonists

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

EGRIFTA WR is injected under the skin of the abdomen once a day.

  • Rotate sites and avoid scars, bruises and the navel.
  • Mix only with the diluent provided and swirl gently. Do not shake.
  • Use only clear, colorless solution.
  • One mixed vial lasts 7 days at room temperature. Do not freeze it.
  • EGRIFTA WR and EGRIFTA SV are different formulations and are not substitutable.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Extra belly fat in adults with HIV and lipodystrophy

Usual dose 1.28 mg once a day
  • 1.28 mg (0.16 mL of the reconstituted solution) injected subcutaneously once daily into the abdomen, rotating injection sites

Good to know

Not substitutable with Egrifta SV; one reconstituted vial provides daily doses for 7 days

See the Full Dosing Instructions on DailyMed →

Side Effects

The most common side effects include:

Common side effects

  • Joint pain
  • Injection site redness, itching or pain
  • Pain in arms or legs
  • Swelling in the hands or feet (peripheral edema)
  • Muscle pain
  • Rash or hives

When to get medical help

  • Get medical help right away for signs of an allergic reaction such as rash, hives, itching, flushing or redness, and stop the medicine.
  • Tell your doctor if you notice swelling, joint pain or carpal tunnel symptoms (hand numbness or tingling) that persist.
  • Tell your doctor about signs of high blood sugar or diabetes, or any vision changes if you already have diabetes.
  • Contact your doctor if cancer returns or you have any new growths.
  • Tell your care team if you become seriously ill, such as after major surgery, trauma or with breathing failure.
  • Stop the medicine and call your doctor if you become pregnant.

Allergic reactions, high blood sugar and fluid retention need prompt attention.

Warnings and Precautions

  • Cancer risk: it raises growth hormone, a growth factor. Do not use it with active cancer. Stop it if cancer returns.
  • High IGF-1: your doctor will monitor levels and may stop the medicine if they stay high.
  • Fluid retention: swelling, joint pain and carpal tunnel syndrome may occur.
  • Blood sugar: it can cause glucose intolerance or diabetes. Check before and during treatment. People with diabetes need eye monitoring.
  • Allergic reactions: they occurred in 4% of patients in trials. Stop it and seek care.
  • Critical illness: stopping may be considered in the critically ill.

Interactions

Tesamorelin may change how some other medicines work.

  • CYP450-metabolized drugs (such as corticosteroids, sex steroids, anticonvulsants, cyclosporine): growth hormone may change how fast they clear.
  • Cortisone acetate or prednisone: you may need higher doses, since growth hormone blocks their activation.

Interactions Listed in the FDA-Approved Label

From the Tesamorelin Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Cytochrome P450-metabolized drugs For example: corticosteroids, sex steroids, anticonvulsants, cyclosporine
    What happensEGRIFTA WR stimulates GH production, and GH may alter the clearance of compounds metabolized by CYP450 liver enzymes; tesamorelin had no significant impact on the pharmacokinetics of simvastatin, a CYP3A substrate, in healthy subjects.
    What to doMonitor patients for potential interactions when giving EGRIFTA WR with other drugs metabolized by CYP450 liver enzymes.
  • Glucocorticoids For example: cortisone acetate and prednisone
    What happensGH inhibits 11βHSD-1, the enzyme that converts cortisone to active cortisol, so patients on glucocorticoid replacement for previously diagnosed hypoadrenalism may be affected; those on cortisone acetate and prednisone may be affected more than others.
    What to doPatients may require an increase in maintenance or stress doses of glucocorticoid after starting EGRIFTA WR.
Read the label’s full interactions text

7 DRUG INTERACTIONS Cytochrome P450-metabolized drugs: Monitor patients for potential interactions when administering with EGRIFTA WR. Glucocorticoids: Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA WR. 7.1 Cytochrome P450-Metabolized Drugs Co-administration of tesamorelin with simvastatin, a CYP3A substrate had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects. EGRIFTA WR stimulates GH production. Published data indicate that GH may modulate cytochrome P450 (CYP450) mediated antipyrine clearance. These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). Monitor patients for potential interactions when administering EGRIFTA WR in combination with other drugs known to be metabolized by CYP450 liver enzymes. 7.2 Glucocorticoids GH inhibits 11β-hydroxysteroid dehydrogenase type 1 (11βHSD-1), a microsomal enzyme required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. EGRIFTA WR stimulates GH production; therefore, patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA WR. Patients treated with cortisone acetate and prednisone may be affected more than others because conversion of these drugs to their biologically active metabolites is dependent on the activity of 11βHSD-1.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Do not use it if you are pregnant.
  • Do not use it with active cancer.
  • Do not use it with pituitary or hypothalamus disruption.
  • Do not use it if you are allergic to it.
  • Mothers with HIV should not breastfeed.
  • It is not for children.
  • There is no information on use in people over 65.

Half-Life and How Your Body Processes It

After an injection under the skin, tesamorelin peaks in the blood in about 9 minutes (0.15 hours). Its half-life is short, about 11 minutes. Absorption was about 34% higher in people with HIV than in healthy people. No formal metabolism studies have been done in humans. Kidney, liver, child and older adult effects have not been established.

Storage

Store EGRIFTA WR 11. Protect from light; excursions permitted to 15°C to 30°C (59°F to 86°F) . Store the Injection box (containing Bacteriostatic Water for Injection, syringes, needles and alcohol swabs) at room temperature at 20°C to 25°C (68°F to 77°F).

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Tesamorelin Injection: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Tesamorelin Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What is tesamorelin injection used for?

It reduces extra belly fat in adults with HIV who have lipodystrophy, meaning abnormal fat distribution. It is not a weight-loss medicine, and it has not been shown to help you stay on your HIV medicines.

How do I use it?

You inject it under the skin of your belly once a day. Rotate spots, and avoid scars, bruises and your navel. Mix it only with the diluent provided, swirl gently without shaking, and use it only if clear. One mixed vial lasts 7 days.

What side effects should I expect?

Common ones include joint pain, muscle pain, pain in the arms or legs, swelling, and redness or itching at the injection site. Rotating injection spots can help with site reactions. Call me or your doctor if swelling or joint pain keeps bothering you.

When should I get urgent help?

If you develop a rash, hives, itching or flushing, stop the medicine and get medical help right away. These can be signs of an allergic reaction.

Can I use it if I am pregnant or breastfeeding?

No. It should not be used in pregnancy because it could harm the baby, so stop it and call your doctor if you become pregnant. Mothers with HIV should not breastfeed.

Will it affect my blood sugar or other medicines?

It can raise blood sugar and sometimes lead to diabetes, so your doctor will check your glucose before and during treatment. It may also change how some medicines are cleared, and people taking cortisone or prednisone replacement may need higher doses.

Is tesamorelin injection available over the counter?

No. Tesamorelin injection is a prescription medicine: every tesamorelin injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was tesamorelin injection first available?

The earliest FDA record we hold for tesamorelin injection is from 2010: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when tesamorelin injection was first used.

What is the brand name of tesamorelin injection?

Tesamorelin injection is the generic name. Its brand names are Egrifta, Egrifta Sv and Egrifta Wr.

What is the generic name of Egrifta?

The generic name of Egrifta is tesamorelin injection. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is tesamorelin injection?

Tesamorelin injection belongs to the drug class Growth Hormone Releasing Factor Analog, its established pharmacologic class on the FDA label.

What strengths does tesamorelin injection come in?

Tesamorelin injection is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (by injection): 2 mg. A listing does not mean every pharmacy stocks every strength.

Where can I read the tesamorelin injection prescribing information (package insert)?

The full FDA-approved prescribing information for tesamorelin injection, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Theratechnologies Inc.'s, revised Jul 29, 2026, and links to it on DailyMed.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Tesamorelin Injection

Skip the scrolling. Ask in your own words and get an answer from Tesamorelin Injection’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Tesamorelin Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Tesamorelin Injection on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Tesamorelin Injection Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Tesamorelin Injection Forms and Strengths (How It Comes)

Tesamorelin Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Tesamorelin Injection inactive ingredients by manufacturer.

Injection

By injection
Brands Egrifta Sv
Available strengths 1 strength
2 FDA-listed product records ⓘ

Tesamorelin Injection on the U.S. Market: Products, Makers and Brands

How Tesamorelin Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 2 Tesamorelin Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2010. Brand names in the directory today include Egrifta Sv and Egrifta Wr; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
3
Brand names ⓘ
2
FDA-listed product records ⓘ
2010
Earliest FDA record ⓘ

How Widely Tesamorelin Injection Is Used (Medicaid Data)

How many Tesamorelin Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

287
Medicaid prescriptions filled (Q1–Q4 2025)
$2.3M paid by Medicaid, before rebates

How commonly is Tesamorelin Injection prescribed? Of the 1,682 medications we measure, Tesamorelin Injection ranks #1,489 by Medicaid prescriptions — more than 11% of them.

Where Tesamorelin Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Tesamorelin Injection product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

tesamorelin 2 MG Injection

287 Medicaid prescriptions (Q1–Q4 2025) 100% of Tesamorelin Injection prescriptions shown $2.3M paid by Medicaid, before rebates ≈ $7,931 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 1044587

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 1 of the 1 listed Tesamorelin Injection NDCs had Medicaid claims.

Compare Tesamorelin Injection Products

A representative set of FDA-listed product records for Tesamorelin Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Route Manufacturer / Labeler Category ⓘ Details
💊Kits
Subcutaneous Theratechnologies Inc. × 2 listings BLA View NDC →

Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Tesamorelin Injection NDCs →

Tesamorelin Injection Side Effects Reported to the FDA (FAERS)

After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Tesamorelin Injection — a signal of what to watch for, not proof the drug caused it.

The effects most often named in FDA reports that mention Tesamorelin Injection are injection site pain, product preparation issue, arthralgia; about 20% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.

1,692
Reports mentioning it
20%
Reported as serious
12
Distinct effects shown
Most reported effects
Injection Site Pain
160
Product Preparation Issue
122
Arthralgia
113
Injection Site Bruising
99
Weight Increased
99
Therapeutic Product Effect Incomplete
86
Injection Site Pruritus
83
Pain In Extremity
75
Fatigue
65
Peripheral Swelling
62
Age groups
Adult · 6

Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Tesamorelin Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.

Tesamorelin Injection FDA Approval History

How Tesamorelin Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.

Tesamorelin Injection was first approved by the FDA in 2010 (Brand: EGRIFTA · Theratechnologies). It remains available in U.S. pharmacies today.

2010
Brand approved
Brand: EGRIFTA · Theratechnologies
2026
Available today
Active in U.S. pharmacies

Source: Drugs@FDA.

Tesamorelin Injection Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Tesamorelin recalls since July 2021.

✅No Tesamorelin recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Tesamorelin Injection in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
1
Strengths
3
Forms in current FDA listings
1 of 1
In current FDA listings No current FDA listing
Ingredient (IN) Tesamorelin Injection RxCUI 1044584
  1. Dose form (SCDF) Injection RxCUI 1719678
    In current FDA listings
    Its 3 strengths (SCD)
    • 1 mg RxCUI 2168763
    • 2 mg RxCUI 1044587
    • 11.6 mg RxCUI 2719314

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Tesamorelin Injection Brand Names

Tesamorelin Injection has 3 brand names on record: Egrifta, Egrifta Sv and Egrifta Wr. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Egrifta the first brand, 2010 Egrifta Sv Egrifta Wr

Who Makes Tesamorelin Injection: Manufacturers and Labelers

One company lists Tesamorelin Injection products with the FDA. By number of product records, the largest are Theratechnologies Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Theratechnologies Inc. 2

Sources for This Tesamorelin Injection Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jul 29, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Tesamorelin Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 2 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
2
Finished products in the current FDA directory
2
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Theratechnologies Inc.
Linked label effective
Jul 29, 2026
Composite sections available
21
Linked SPL Set ID
839334d3-8c1d-4c26-9036-2ab524a6ea75
Linked SPL Document ID
285bfbe0-2839-441c-9d4d-990b6f413e7b
Open the linked representative label on DailyMed ↗
NDC package records associated with this linked SPL 1

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Theratechnologies Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →